Business Standard

Monday, December 23, 2024 | 04:24 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Biocon gains over 7% after receiving EIR from USFDA

The stock surged 7% to Rs 420 on the BSE in early morning deal, trading close to its 52-week high of Rs 424 touched on July 19, 2017 in intra-day trade

Biocon
Premium

Biocon

SI Reporter Mumbai
Biocon surged 7% to Rs 420 on the BSE in early morning trade after the company said its facility received Establishment Inspection Report (EIR) with VAI (voluntary action indicated) status and closed the inspection.

The stock is trading close to its 52-week high of Rs 424 touched on July 19, 2017 in intra-day trade.

“The company confirms that the US Food and Drug Administration (FDA) has issued an EIR in relation to the cGMP (current Good Manufacturing Practice) inspection of its aseptic drug product facility that was audited between 25th May – 3rd June 2017,” Biocon said in

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in